ArticlePloS one2017

Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.

Billy Amzal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.